The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress

Perfusion

Volumn 24, Issue 4, 2009, Pages 231-237

  Sohn, N ^a   Marcoux, J ^b   Mycyk, T ^b   Krahn, J ^a   Meng, Qh ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

biocompatible coating material; cardiopulmonary bypass; coronary artery bypass grafting; inflammatory response; oxidative stress

Indexed keywords

BIOLINE; BIOMATERIAL; INTERLEUKIN 10; INTERLEUKIN 6; MYELOPEROXIDASE; NITRIC OXIDE; PHOSPHORYLCHOLINE; POLYMETHOXYETHYL ACRYLATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; PEROXIDASE;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; BLOOD SAMPLING; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CARDIOPULMONARY BYPASS CIRCUIT; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEVICE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; INTERNAL MAMMARY ARTERY; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SAPHENOUS VEIN GRAFT; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HEART INFARCTION; MIDDLE AGED;

AGED; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY BYPASS; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE; OXIDATIVE STRESS; PEROXIDASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75649096453     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659109351218     Document Type: Article

References (25)

1. Edmunds LH Cardiopulmonary bypass after 50 years. N Engl J Med 2004 ; 351: 1603-1606.
2. Quaniers JM, Leruth J., Albert A., et al. Comparison of inflammatory responses after off-pump and on-pump coronary surgery using surface modifying additives circuit. Ann Thorac Surg 2006 ; 81: 1683-1690.
3. Suleiman MS, Zacharowski K., Angelini GD Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. Brit J Pharm 2008 ; 153: 21-33.
4. Benedicta Dsouza A., Vishwanath P., Dsouza V. Oxidative injury and antioxidants in coronary bypass graft surgery: off-pump CABG significantly reduces oxidative stress. Clin Chim Acta 2007 ; 375: 147-152.
5. Kozik DJ, Tweddell JS Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2006 ; 81: S2347-2354.
6. Rubens FD, Mesana, T. The inflammatory response to cardiopulmonary bypass: a therapeutic overview. Perfusion 2004 ; 19: S5 - S12.
7. Paparella D., Al Radi OO, Meng QH, et al. The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass. Blood Coagul Fibrinolysis 2005 ; 16: 323-328.
8. Meng QH, Zhu S., Sohn N., et al. Release of cardiac biochemical and inflammatory markers in patients on cardiopulmonary bypass undergoing coronary artery bypass grafting. J Card Surg 2008 ; 23: 681-687.
9. Laffey JG, Boylan JF, Cheng DC The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002 ; 97: 215-252.
10. Levy JH, Tanaka KA Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003 ; 75: S715-20.
11. Berg K., Haaverstad R., Astudillo R., et al. Oxidative stress during coronary artery bypass operations: importance of surgical trauma and drug treatment. Scan Cardiovascular J 2006 ; 40: 291-297.
12. Hayashi Y., Sawa Y., Nishimura M., et al. Peroxynitrite, a product between nitric oxide and superoxide anion, plays a cytotoxic role in the development of post-bypass systemic inflammatory response. Eur J Cardiothorac Surg 2004 ; 26: 276-280.
13. Kutay V., Noyan T., Ozcan S., et al. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits. J Card Surg 2006 ; 21: 572-577.
14. Biglioli P., Cannata A., Alamanni F., et al. Biological effects of off-pump vs. on-pump coronary artery surgery: focus on inflammation, hemostasis and oxidative stress. Eur J Cardiothorac Surg 2003 ; 24: 260-269.
15. Schmid FX, Floerchinger B., Vudattu NK, et al. Direct evidence of endothelial injury during cardiopulmonary bypass by demonstration of circulating endothelial cells. Perfusion 2006 ; 21: 133-137.
16. Gourlay T. Biomaterial development for cardiopulmonary bypass. Perfusion 2001 ; 16: 381-390.
17. Gunaydin S. Emerging technologies in biocompatible surface modifying additives: quest for physiological cardiopulmonary bypass. Curr Med Chem-Cardiovascular & Hematological Agents 2004 ; 2: 187-196.
18. Belway D., Rubens FD Currently available biomaterials for use in cardiopulmonary bypass. Expert Rev Med Devices 2006 ; 3: 345-355.
19. Jordan SW, Chaikof EL Novel thromboresistant materials. J Vas Surg 2007 ; 45: 104A - 115A.
20. Olsson C., Siegbahn A., Henze A., et al. Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric heart surgery. Scand Cardiovasc J 2000 ; 34: 33-40.
21. Palatianos GM, Foroulis CN, Vassili MI, et al. A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit. Ann Thorac Surg 2003 ; 76: 129-135.
22. De SF, Van BY, Caes F., et al. Phosphorylcholine coating offers natural platelet preservation during cardiopulmonary bypass. Perfusion 2002 ; 17: 39-44.
23. Hsu LC Heparin-coated cardiopulmonary bypass circuits: current status. Perfusion 2001 ; 16: 417-428.
24. de Vroege R., van Oeveren W., van Klarenbosch J., et al. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Anesth Analg 2004 ; 98: 1586-1594.
25. Karlsson K., Marklund SL Heparin-induced release of extracellular superoxide dismutase to human blood plasma. Biochem J 1987 ; 242: 55-59.